Opzelura (ruxolitinib) cream received FDA approval for the treatment of vitiligo in July 2022 [1]. This approval specifically covers repigmentation in adults and children 12 years of age and older with nonsegmental vitiligo [2].
What is Vitiligo and How Does Opzelura Treat It?
Vitiligo is a condition characterized by the loss of skin color, resulting in depigmented patches. Opzelura is a topical formulation of ruxolitinib, a Janus kinase (JAK) inhibitor. By inhibiting JAK enzymes, Opzelura is thought to interrupt signaling pathways involved in inflammation and immune responses that contribute to vitiligo [3]. The cream is applied to the affected skin areas to promote repigmentation [2].
When Did Opzelura First Receive FDA Approval for Other Conditions?
Before its approval for vitiligo, Opzelura was approved by the FDA in September 2021 for the topical treatment of chronic graft versus host disease (cGVHD) in patients 12 years and older whose disease is no longer adequately managed by corticosteroid therapy or another systemic treatment [4].
How Effective is Opzelura for Vitiligo?
Clinical trials demonstrated that Opzelura cream led to significant repigmentation in patients with vitiligo. In one study, a substantial percentage of participants achieved at least a 10% facial area skin repigmentation score, and a notable proportion also saw repigmentation in other body areas after 24 weeks of treatment [2]. The efficacy and safety data supporting the approval are available from these clinical studies [2].
What Are the Potential Side Effects of Opzelura?
Common side effects associated with Opzelura cream include acne, redness, itching, rash, pain, and irritation at the application site [3]. More serious potential side effects, as identified in clinical trials for its other approved indication, can include serious infections, malignancy, and thrombotic events (blood clots) [4]. Patients should discuss all potential risks and benefits with their healthcare provider [3, 4].
Can Opzelura Be Used by Children?
Yes, Opzelura is approved for use in children 12 years of age and older with nonsegmental vitiligo [2].
What Are the Patent Expiration Dates for Opzelura?
Information on patent expiration dates for Opzelura can be found on DrugPatentWatch.com [1]. Patent exclusivity can influence the availability and pricing of generic alternatives.
Are There Other Treatments for Vitiligo?
Other treatment options for vitiligo may include phototherapy, topical corticosteroids, and surgical procedures, depending on the individual's condition and needs [5]. Opzelura offers a different mechanism of action as a topical JAK inhibitor [3].
Sources:
[1] DrugPatentWatch.com
[2] FDA approval announcement regarding Opzelura for vitiligo
[3] Opzelura prescribing information
[4] FDA approval announcement regarding Opzelura for cGVHD
[5] National Institutes of Health (NIH) information on vitiligo